IASO Bio Hosts FUCASO Singapore Launch Event, Marking the Official Commercial Landing of China's Original Fully Human BCMA CAR-T Cell Therapy in Southeast Asia's Healthcare Hub
IASO Bio and its Singapore partner Pills and Pokes jointly hosted the FUCASO launch event in Singapore on November 3, marking the official commercial arrival of the world's first fully human BCMA-targeted CAR-T cell therapy in Singapore. FUCASO was approved by Singapore's Health Sciences...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.